FDA grants En­her­tu tu­mor-ag­nos­tic ac­cel­er­at­ed ap­proval

The FDA on Fri­day gave Dai­ichi Sankyo and As­traZeneca’s an­ti­body-drug con­ju­gate En­her­tu a tu­mor-ag­nos­tic in­di­ca­tion un­der ac­cel­er­at­ed ap­proval. It’s the first such ap­proval for a HER2-di­rect­ed ther­a­py — and the first an­ti­body-drug con­ju­gate to get a tu­mor-ag­nos­tic in­di­ca­tion from the FDA.

The FDA ap­proved En­her­tu for adults with ad­vanced HER2-pos­i­tive sol­id tu­mors who have re­ceived pri­or sys­temic treat­ment and have no good op­tions left. The block­buster an­ti­body-drug con­ju­gate was pre­vi­ous­ly ap­proved for cer­tain breast can­cer, lung can­cer and stom­ach can­cer pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER